Everolimus with first-line hormone therapy for specific breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial tests whether adding everolimus to standard first-line hormone (endocrine) therapy can better control a certain type of advanced breast cancer. It is designed for people whose tumor matches a specific “SNF1 subtype.”
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75
- Your breast cancer has HR-positive and HER2-negative results from tumor tests
- Your tumor is confirmed as the SNF1 subtype using special digital pathology on biopsy tissue
- You have advanced or metastatic disease that can’t be fully treated with surgery/radiation, and you have not previously had treatment for advanced/metastatic breast cancer
- Your last treatment with targeted CDK4/6 drugs is either never, or it ended at least 1 year ago
- You have enough healthy blood and organ function for study drugs, and your mobility score is ECOG 0–1
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
This study tests whether adding a drug called everolimus to a targeted therapy called trastuzumab rezetecan is more effective than the targeted therapy alone for people with a specific type of triple-negative breast cancer (called LAR subtype) that has spread or come back. The combination aims to improve treatment response and potentially help you live longer.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This Phase 2 study tests a genetically guided treatment plan for ER-positive breast cancer that has progressed after CDK4/6 therapy. It may help by matching treatment to tumor genetic changes.
This trial tests a new form of the drug sirolimus (bound to albumin) combined with two other drugs (palbociclib and fulvestrant) for advanced breast cancer. It aims to see if this combination is safe and effective for people with the HR-positive, HER2-negative subtype.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.